search icon

    Market Snapshot

    blog search icon

    MTNB Stock Price History and Quote Analysis: Insights for Investors

    Matinas BioPharma Holdings, Inc.

    (AMEX:MTNB)

    $0.419

    0.01 (1.65%)

    At Close: 4:00 PM

    $0.43

    0.02 (4.39%)

    Pre Market: 7:21 AM

    MTNB Stock Price Graph

    • 1D
    • 5D
    • 1M
    • 3M
    • 6M
    • 1Y
    • YTD
    • All

    MTNB Stock Price Today

    Matinas BioPharma Holdings, Inc. (MTNB) stock rallied over 1.65% intraday to trade at $0.4187 a share on AMEX. The stock opened with a gain of 2.45% at $0.422 and touched an intraday high of $0.435, rising 1.65% against the last close of $0.412. The Matinas BioPharma Holdings, Inc. in stock market went to a low of $0.407 during the session.

    MTNB Stock Snapshot

    $0.412

    Prev. Close

    105.51 Million

    Market Cap

    $0.407

    Day Low

    $0.422

    Open

    216.87 Million

    Number of Shares

    $0.435

    Day High

    -

    P/E ratio

    -0.11

    EPS (TTM)

    0.15

    Cash Flow per Share

    0.74

    Free Float in %

    0.30

    Book Value

    213,023

    Volume

    Contact Details

    1545 Route 206 South
    Suite 302
    Bedminster, NJ 07921
    United States

    Website:https://www.matinasbiopharma.com

    Contact #:908 484 8805

    Company Information

    Employees31

    Beta2.05

    Sales or Revenue$2.12 Million

    5Y Sales Change-

    Fiscal Year EndsDec. 2021

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

    Frequently Asked Questions

    icon

    What is the current Matinas BioPharma Holdings, Inc. (MTNB) stock price?

    Matinas BioPharma Holdings, Inc. (AMEX: MTNB) stock price is $0.42 in the last trading session. During the trading session, MTNB stock reached the peak price of $0.435 while $0.407 was the lowest point it dropped to. The percentage change in MTNB stock occurred in the recent session was 1.65% while the dollar amount for the price change in MTNB stock was $0.01.

    icon

    MTNB's industry and sector of operation?

    The AMEX listed MTNB is part of Biotechnology industry that operates in the broader Health Care sector. Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.

    icon

    Who are the executives of MTNB?

    Mr. Jerome D. Jabbour J.D.
    Co-Founder, Chief Executive Officer, Pres & Director
    Dr. Raphael J. Mannino Ph.D.
    Chief Scientific Officer
    Mr. Frank Calamusa
    Executive Director and Head of Manufacturing & Supply Chain
    Mr. Jerome D. Jabbour J.D.
    Co-Founder, CEO, Pres & Director

    icon

    How MTNB did perform over past 52-week?

    MTNB's closing price is 0.08% higher than its 52-week low of $0.389 where as its distance from 52-week high of $1 is -0.58%.

    icon

    How many employees does MTNB have?

    Number of MTNB employees currently stands at 31. MTNB operates from 1545 Route 206 South, Suite 302, Bedminster, NJ 07921, United States.

    icon

    Link for MTNB official website?

    Official Website of MTNB is: https://www.matinasbiopharma.com

    icon

    How do I contact MTNB?

    MTNB could be contacted at phone #908 484 8805 and can also be accessed through its website. MTNB operates from 1545 Route 206 South, Suite 302, Bedminster, NJ 07921, United States.

    icon

    How many shares of MTNB are traded daily?

    MTNB stock volume for the day was 213,023 shares. The average number of MTNB shares traded daily for last 3 months was 308.56 Thousands.

    icon

    What is the market cap of MTNB currently?

    The market value of MTNB currently stands at $105.51 Million with its latest stock price at $0.42 and 216.87 Million of its shares outstanding.